Ultragenyx Pharmaceutical Inc. Net Cash Provided by (Used in) Financing Activities in USD from Q1 2013 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Ultragenyx Pharmaceutical Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2013 to Q1 2025.
  • Ultragenyx Pharmaceutical Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2025 was $157M.
  • Ultragenyx Pharmaceutical Inc. annual Net Cash Provided by (Used in) Financing Activities for 2024 was $399M, a 2.86% increase from 2023.
  • Ultragenyx Pharmaceutical Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $388M, a 22.6% decline from 2022.
  • Ultragenyx Pharmaceutical Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $501M, a 323% increase from 2021.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Net Cash Provided by (Used in) Financing Activities, Annual (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Annual Growth (%)

Ultragenyx Pharmaceutical Inc. Quarterly Net Cash Provided by (Used in) Financing Activities (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 $157M +$157M Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q1 2024 -$58K* +$664K Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q1 2023 -$722K -$2.33M -145% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q1 2022 $1.61M -$11M -87.3% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q1 2021 $12.6M -$43M -77.3% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-06
Q1 2020 $55.6M -$298M -84.3% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q1 2019 $354M +$67.2M +23.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q1 2018 $286M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q1 2014 $122M +$122M Jan 1, 2014 Mar 31, 2014 10-Q 2014-05-12
Q1 2013 $1K* Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-12

Ultragenyx Pharmaceutical Inc. Annual Net Cash Provided by (Used in) Financing Activities (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $399M +$11.1M +2.86% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-19
2023 $388M -$113M -22.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-19
2022 $501M +$383M +323% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-19
2021 $119M -$482M -80.3% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-21
2020 $600M -$79M -11.6% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-17
2019 $679M +$342M +102% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $337M +$201M +147% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-12
2017 $136M -$2.41M -1.74% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-14
2016 $139M Jan 1, 2016 Dec 31, 2016 10-K 2019-02-20
* An asterisk sign (*) next to the value indicates that the value is likely invalid.